From the Journals

Breast cancer care delayed when patients have high deductibles


 

FROM JOURNAL OF CLINICAL ONCOLOGY


Compared with controls, the hazard ratios (HR) for each parameter were as follows:

Time to first diagnostic breast imaging: HR = 0.96 (95% confidence interval 0.94-0.96)

Time to first breast biopsy: HR = 0.92 (0.89-0.95)

Time to early stage breast cancer diagnosis: HR = 0.83 (0.78-0.90)

Time to breast cancer chemotherapy: HR = 0.79 (0.72-0.86)

“The findings imply that the high out-of-pocket obligations under HDHPs [high-deductible health plans] might be a barrier to timely receipt of essential breast cancer services. Women in HDHPs might either delay presenting for concerning symptoms or, if proceeding along the pathway from breast cancer screening to diagnostic testing to treatment, be hesitant to undergo subsequent (and generally more expensive) care,” the authors wrote.

They noted that initially modest delays in diagnostic imaging appeared to snowball into longer delays as women proceeded through stages of care.

They recommend a strategy whereby insurers carve out exemptions to high deductibles for services such as diagnostic imaging and breast biopsy.

SOURCE: Wharam et al. J Clin Oncol. 2018 Feb 28. doi: 10.1200/JCO.2017.75.2501.

Pages

Recommended Reading

Shaping practice: Z1071 continues to redefine axillary management
MDedge Family Medicine
VIDEO: Weight loss cut risk of breast cancer
MDedge Family Medicine
Extra years of adjuvant bisphosphonate not needed in early breast cancer
MDedge Family Medicine
Postmenopausal women who shed pounds see lower breast cancer risk
MDedge Family Medicine
POSH study: BRCA mutations did not influence survival in young onset breast cancer
MDedge Family Medicine
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Family Medicine
STUDY: More mammograms after cost-sharing elimination
MDedge Family Medicine
AHA: Heart health helps optimize breast cancer outcomes
MDedge Family Medicine
Breast cancer deaths projected for 2018
MDedge Family Medicine
FDA authorizes first direct-to-consumer BRCA1/2 test
MDedge Family Medicine